Welcome back,

Remission is within reach – Target the underlying drivers of inflammation with benralizumab

20 Sep 2022

Share

Login

Get access to our exclusive articles.

Related articles

CONFERENCE UPDATE

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2
INDUSTRY ESSENTIALS

Bridging practice and precision for early-stage resectable NSCLC: Malaysia’s first surgical consensus
CONFERENCE UPDATE

AI-assisted screening detects early-stage lung cancer in high-risk never-smokers: Interim results from the local LC-SHIELD study
CONFERENCE UPDATE

Nivolumab + chemotherapy improves long-term survival outcomes in resectable NSCLC: Final OS analysis from the CheckMate 816 trial
CONFERENCE UPDATE

From SABA reliance to ICS-first: Malaysia’s 2024 CPG ushers in a new era of asthma control